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ABSTRACT 
Technological advances in radiation therapy delivery have 
permitted the use of high dose per fraction radiotherapy for 
early stage prostate cancer. Level I  evidence supporting 
the safety and efficasy of hypofractionated radiotherapy is 
evolving. Moderate and extreme hypofractionation regimens 
show promising cancer control but long term results of 
noninferiority studies of both modalities are required before 
use in routine treatment as standard of care. 
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Introduction
a good therapeutic outcome in radiotherapy comprises both 
local control of the tumor and minimal late normal tissue 
complications. Recent advances in radiotherapy technologies 
have sparked interest in hypofractionation utilizing targeting 
to minimize normal tissue injury rather than dose modulation. 
Beyond biology, hypofractionation for prostate cancer has 
the advantages of increased convenience for the patient and 
a lower cost burden for the health care system. 
Curative radiotherapy treatment regimens involve 
dividing the overall radiation dose into a number of fractions, 
as this takes advantage of the five Rs of radiotherapy: 
reoxygenation of hypoxic cells, repopulation of cells, repair 
of normal tissue, redistribution of cells through the cell cycle 
and differences in the intrinsic radiosensitivity of tumor cells 
compared with normal tissue cells. A typical conventional 
fractionation regimen uses 2 Gy daily doses delivered five 
times a week, up to a total of 60-80 Gy. A good therapeutic 
outcome in radiotherapy comprises both local control of the 
tumor and minimal late normal tissue complications. As the 
dose per fraction increases, the probability of toxic effects in 
late responding normal tissue increases disproportionately 
compared with early responding normal tissues, which 
are typically less sensitive to fractionation. It is primary 
late responding normal tissue toxicity that typically limits 
radiotherapy treatment regimens.
Recent advances in radiotherapy technologies have 
sparked interest in hypofractionation, a highly conformal 
radiotherapy delivering daily doses of 2.5-10 Gy, utilizing 
targeting to minimize normal tissue injury rather than 
dose modulation. The biologic rationale for applying 
hypofractionation to prostate cancer is based on the theory 
that the slow proliferation of prostate cancer cells leads to 
a biologic radiation response in prostate cancer that differs 
from most other cancers. Traditional fractionation causes the 
accumulation of DNA damage, ultimately causing apoptosis, 
mitotic catastrophe, or senescence. A slow proliferation 
rate results in a high reparation ability of radiation damage 
over time, such that standard fractionation given in small 
increments over a long time period may be suboptimal for 
prostate cancer for which a high total dose is required for 
effective control. For slowly proliferating cells high doses 
per fraction may be more effective because immediate cell 
death is instigated due to high number of DNA double strand 
breaks caused by each fraction.
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Beyond biology, hypofractionation for prostate cancer 
has the advantages of increased convenience for the patient 
and a lower cost burden for the health care system. 
Hypofractionation has arisen in the setting of an 
increased ability to plan and target radiotherapy to a given 
target. In the case of curative radiotherapy of prostate cancer 
the use of intensity-modulated radiation therapy (IMRT) has 
allowed highly conformal treatment plans where the dose 
gradient is quite steep, allowing for reduced dose to nearby 
normal tissues. Image guided radiation therapy (IGRT) via 
ultrasound, x-ray, or computed tomography imaging of the 
prostate allows proper placement of the radiation fields 
each day. Most of the studies utilizing hypofractionation 
deliver the radiation dose using IMRT with image guidance, 
although several older studies were performed with 3D 
conformal radiotherapy.  Extreme hypofractionation also 
known as stereotactic body radiation therapy (SBRT) is 
often delivered using a specialized linear accelerator on a 
robotic arm, but it can be delivered by any accelerator with 
IMRT and on board imager. 
Moderate hypofractionation
There are many reports of moderate hypofractionation using 
external beam radiotherapy, with doses per fraction varying 
from 2.5 to 3.16 Gy. The largest of these is the CHHiP study, 
which randomized patients between 2 Gy per fraction (to 
74 Gy in 37 fractions) or hypofractionated (60 Gy in 20 
fractions or 57 Gy in 19 fractions) IMRT [1]. This trial has 
recruited over 3000 men and has now published data from 
interim safety analysis of the first 457 patients randomized. 
Late toxicity measured at two years after treatment was 
low for all arms. RTOG grade ≥2 gastrointestinal toxicity 
seen in 4.3, 3.6 and 1.4% in the 74, 60, and 57 Gy arms, 
respectively. Acute toxicity of RTOG grade 2 or higher was 
seen in 0.8-2.3% (GI) and 7-7.6% (GU). Acute toxicity had 
a brisker onset and a higher peak for the hypofractionated 
arms compared with the conventional fractionation. Acute 
toxicity was also noted to return to baseline more quickly in 
the experimental arms.
Arcangeli et al. [2] randomized 168 patients to 62 Gy 
in 20 fractions or 80 Gy in 40 fractions. Although the trial 
was small contemporary prescriptions and 3D conformal 
techniques were used, with all patients receiving 9 months 
of androgen suppression. Doses were iso-effective based 
on an alpha/beta ratio of 1.5 or 1.8 Gy (EQD2 81.5 or 79.9 
Gy, respectively). The late toxicity was not significantly 
different between the hypofractionated and conventionally 
fractionated arms. (LENT-SOMA GI and GU toxicity ≥ 
grade 2 was 17 and 16% in the hypofractionated arm at 3 years 
compared with 14 and 11% in the conventional arm). Acute 
toxicity was acceptable and comparable with that of CHHiP. 
It was also noted that the hypofractionated arm had a non-
significant increase in acute toxicity. The bRFS at 3 years 
was significantly improved in the hypofractionated arm, but 
the difference was marginal (87% vs 79%, p=0.035) [2] and 
no longer significant at 5 years (85% vs79%, p=0.065) [3]. 
In addition the trial’s primary end point was acute toxicity 
and, therefore was not adequately statistically powered to 
formally assess biochemical control.
Pollack et al. [4] reported the outcomes of the first 
100 patients randomized to 76 Gy in 38 fractions versus 
70.2Gy in 26 fractions. No differences in maximal acute 
toxicity were seen, but a small increase in acute GI toxicity 
was noted during treatment. A 5-year update of this work 
showed no difference in biochemical outcomes [5]. The MD 
Anderson Cancer Center randomized 204 men to 75.6 Gy 
in 42 fractions versus 72 Gy in 30 fractions and found no 
significant difference in 5-year bRFS or toxicity [6].
Therefore the data from randomized trials to date can be 
interpreted as having iso-effective and iso-toxic late effects, 
with a possible marginal biochemical control benefit to 
biological dose escalation with moderate hypofractionation. 
As yet, moderate hypofractionation cannot be proven to be 
superior to conventional fractionation, but we can conclude 
that it seems to be safe and feasible without a significant 
increase in toxicity.
Extreme hypofractionation
Only phase 2 prospective studies of extreme hypofractionation 
with daily doses of 5-10 Gy to 35-50 Gy have been 
published, with follow up ranging from 18 months to 4.6 
years. In general, these studies included only low risk and 
selected intermediate risk patients. In this patient population 
early cancer outcomes have been excellent. In the largest 
study with a follow up of 4.6 years Katz et al [7] treated 515 
patients to 35-36.25 Gy in 5 fractions. Low risk patients had 
a freedom from biochemical failure rate of 97% at 6 years. 
Results for intermediate and high risk patients were 92% 
and 70%, respectively. Loblaw et al [8] treated only low 
risk prostate cancer patients and had a similar follow up of 
55 months. The authors noted a 5-year biochemical control 
of 98%. This study included posttreatment biopsies; 85% 
of the patients underwent biopsies with only 4% returning 
positive for residual cancer 3 years after treatment. Theses 
excellent results are early yet given the natural history of late 
recurrence in prostate cancer, but at 5 years they are similar 
to a high dose IMRT series for low risk disease [9].
 Unfortunately, theses studies have not been randomized, 
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and although supportive of the concept of hypofractionation, 
they cannot be used to direct routine care off protocol.
Moderate to high-grade acute toxicity from extreme 
hypofractionation ranges between 10% and 20% in these 
studies, with urinary symptoms more common than those 
relative to bowel and rectum. Late grade ≥2 toxicity 
rates from these individual institutional experiences vary 
significantly (1-31%), with occasional grade 4 toxicities 
reported. While urinary incontinence is uncommon in 
conventional fractionation, in one study it was reported as 
high as 10% in previously continent men 3 years post SBRT 
[10].
Conclusion
Given the demonstration thus far of at least comparable 
toxicities and biochemical outcomes for moderate 
hypofractionation, it is possible that with further evidence 
from maturing data, shorter regimens become the standard 
of care for prostate cancer. Whilst the evidence for extreme 
hypofractionation continues to accrue and with two 
randomized trials now recruiting, the clinical benefit, or 
otherwise, of SBRT will become clearer. 
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